Just saw Organon's latest data on VTAMA for pediatric atopic dermatitis and it's actually pretty interesting. They tested it on kids as young as 2 years and showed real improvements in sleep quality within the first week or two — which honestly matters way more than people realize. Sleep disruption is a huge deal for families dealing with severe AD, so this isn't just another clinical win on paper.

The Phase 3 ADORING trials included 654 pediatric patients and the results held up across different age groups, which is solid. FDA already approved it last December for AD in kids and adults, so this new sleep data is basically reinforcing why it could be a game-changer. Allergy specialists and dermatologists are probably going to be paying attention to this since patient-reported outcomes like sleep are becoming a bigger part of prescribing decisions.

Market-wise, the AD drug space is projected to hit $17.21 billion by 2026 with 7.7% annual growth, so there's definitely room for products that actually improve quality of life. OGN stock only moved 0.8% on the news though, which feels like the market's still digesting it. Worth watching how this plays out.